Allogene Therapeutics (ALLO) Long-Term Investments (2018 - 2026)

Allogene Therapeutics has reported Long-Term Investments for 8 years, with the latest figure at $8.0 million in Q4 2025.

• Quarterly Long-Term Investments fell 90.03% year-over-year to $8.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.0 million (down 90.03% YoY) and the FY2025 annual result came in at $8.0 million, down 90.03% from the prior year.
• Long-Term Investments slipped to $8.0 million in Q4 2025 per ALLO's latest filing, from $24.9 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $378.2 million in Q3 2021 and troughed at $1.1 million in Q2 2024.
• A 5-year average of $66.9 million and a median of $24.9 million in 2025 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2021 and 2024: Long-Term Investments soared 8275.16% in 2021, then sank 97.84% in 2024.
• Over 5 years, Long-Term Investments stood at $352.2 million in 2021, then sank by 95.08% to $17.3 million in 2022, then surged by 85.77% to $32.2 million in 2023, then soared by 150.77% to $80.7 million in 2024, then plunged by 90.03% to $8.0 million in 2025.
• According to Business Quant data, Long-Term Investments over the past three periods registered $8.0 million, $24.9 million, and $29.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.